The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature
Background: Squamous cell carcinoma (SCC) of the lip is a distinct subtype of oral cavity SCC, accounting for about 10–20 % of all oral cavity cancers. According to National Comprehensive Cancer Network (NCCN) guidelines, treatment consists of surgical resection with adjuvant radiotherapy or chemora...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024003716 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553658867613696 |
|---|---|
| author | Ido Amir Nir Tsur Itamar Averbuch Gideon Bachar Noga Kurman |
| author_facet | Ido Amir Nir Tsur Itamar Averbuch Gideon Bachar Noga Kurman |
| author_sort | Ido Amir |
| collection | DOAJ |
| description | Background: Squamous cell carcinoma (SCC) of the lip is a distinct subtype of oral cavity SCC, accounting for about 10–20 % of all oral cavity cancers. According to National Comprehensive Cancer Network (NCCN) guidelines, treatment consists of surgical resection with adjuvant radiotherapy or chemoradiotherapy as indicated. The role of immunotherapy as a treatment modality remains unclear. Methods: We identified six patients with SCC of the lip who had locally advanced or recurrent disease and treated with PD-1 inhibitors, either as monotherapy or as part of a chemo-immuno regimen. Three patients were diagnosed with locoregional recurrences after conventional treatment failure, one of whom concurrently diagnosed with distant metastases. Two cases involved treatment with immunotherapy as an alternative to surgery or radiotherapy. Clinical and radiological responses were assessed, and side effects were recorded. Results: All patients exhibited complete clinical response, five showed complete radiological responses per PET-CT. One patient was yet to be assessed radiologically. Another had a PET-avid supraclavicular node negative for malignancy. The median follow-up time since treatment initiation was 11.49 months (IQR 7.77 - 29.03). Adverse effects included severe myositis (n = 1), arthralgia (n = 1), psoriasis (n = 1), esophagitis (n = 1), mild hepatitis (n = 1) and pruritus (n = 2). Management included corticosteroids (topical or systemic) and/or 2nd generation antihistamines and treatment cessation as indicated. Conclusion: Immunotherapy shows promise for lip SCC after conventional treatment failure or as an alternative to surgery or radiotherapy in unsuitable candidates, suggesting a tumor biology resembling cutaneous rather than oral cavity SCC. Patients should be closely monitored for potential side effects. |
| format | Article |
| id | doaj-art-2e2eccb4884e4c9b8cc484b3c61cf5db |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-2e2eccb4884e4c9b8cc484b3c61cf5db2025-01-09T06:16:38ZengElsevierOral Oncology Reports2772-90602024-06-0110100525The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literatureIdo Amir0Nir Tsur1Itamar Averbuch2Gideon Bachar3Noga Kurman4Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel; Otolaryngology-Head and Neck Surgery Department, Rabin Medical Center, Petah-Tikva, 4941492, Israel; Corresponding author.Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel; Otolaryngology-Head and Neck Surgery Department, Rabin Medical Center, Petah-Tikva, 4941492, IsraelFaculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel; Oncology Department, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, 4941492, IsraelFaculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel; Otolaryngology-Head and Neck Surgery Department, Rabin Medical Center, Petah-Tikva, 4941492, IsraelFaculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel; Oncology Department, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, 4941492, IsraelBackground: Squamous cell carcinoma (SCC) of the lip is a distinct subtype of oral cavity SCC, accounting for about 10–20 % of all oral cavity cancers. According to National Comprehensive Cancer Network (NCCN) guidelines, treatment consists of surgical resection with adjuvant radiotherapy or chemoradiotherapy as indicated. The role of immunotherapy as a treatment modality remains unclear. Methods: We identified six patients with SCC of the lip who had locally advanced or recurrent disease and treated with PD-1 inhibitors, either as monotherapy or as part of a chemo-immuno regimen. Three patients were diagnosed with locoregional recurrences after conventional treatment failure, one of whom concurrently diagnosed with distant metastases. Two cases involved treatment with immunotherapy as an alternative to surgery or radiotherapy. Clinical and radiological responses were assessed, and side effects were recorded. Results: All patients exhibited complete clinical response, five showed complete radiological responses per PET-CT. One patient was yet to be assessed radiologically. Another had a PET-avid supraclavicular node negative for malignancy. The median follow-up time since treatment initiation was 11.49 months (IQR 7.77 - 29.03). Adverse effects included severe myositis (n = 1), arthralgia (n = 1), psoriasis (n = 1), esophagitis (n = 1), mild hepatitis (n = 1) and pruritus (n = 2). Management included corticosteroids (topical or systemic) and/or 2nd generation antihistamines and treatment cessation as indicated. Conclusion: Immunotherapy shows promise for lip SCC after conventional treatment failure or as an alternative to surgery or radiotherapy in unsuitable candidates, suggesting a tumor biology resembling cutaneous rather than oral cavity SCC. Patients should be closely monitored for potential side effects.http://www.sciencedirect.com/science/article/pii/S2772906024003716Lip squamous cell carcinoma (SCC)ImmunotherapyPD-1 inhibitorsImmune checkpoint inhibitors (ICIs)Oral cavity squamous cell carcinoma (OCSCC) |
| spellingShingle | Ido Amir Nir Tsur Itamar Averbuch Gideon Bachar Noga Kurman The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature Oral Oncology Reports Lip squamous cell carcinoma (SCC) Immunotherapy PD-1 inhibitors Immune checkpoint inhibitors (ICIs) Oral cavity squamous cell carcinoma (OCSCC) |
| title | The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature |
| title_full | The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature |
| title_fullStr | The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature |
| title_full_unstemmed | The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature |
| title_short | The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature |
| title_sort | role of immunotherapy in the treatment of lip squamous cell carcinoma a series of six cases and a review of the current literature |
| topic | Lip squamous cell carcinoma (SCC) Immunotherapy PD-1 inhibitors Immune checkpoint inhibitors (ICIs) Oral cavity squamous cell carcinoma (OCSCC) |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024003716 |
| work_keys_str_mv | AT idoamir theroleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT nirtsur theroleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT itamaraverbuch theroleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT gideonbachar theroleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT nogakurman theroleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT idoamir roleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT nirtsur roleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT itamaraverbuch roleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT gideonbachar roleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature AT nogakurman roleofimmunotherapyinthetreatmentoflipsquamouscellcarcinomaaseriesofsixcasesandareviewofthecurrentliterature |